350 related articles for article (PubMed ID: 28645563)
61. Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Tsai JJ; Hsu FT; Pan PJ; Chen CW; Kuo YC
Anticancer Res; 2018 Apr; 38(4):2119-2125. PubMed ID: 29599330
[TBL] [Abstract][Full Text] [Related]
62. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
63. Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
Qiu YQ; Zhou J; Kang XS; Ding LM; Yu W; Tan FL; Deng DF
Sci Rep; 2014 Mar; 4():4324. PubMed ID: 24632756
[TBL] [Abstract][Full Text] [Related]
64. Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation.
Jiang N; Chen WJ; Zhang JW; Xu C; Zeng XC; Zhang T; Li Y; Wang GY
Oncotarget; 2015 Apr; 6(10):7866-79. PubMed ID: 25797263
[TBL] [Abstract][Full Text] [Related]
65. Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.
Pramanik KC; Fofaria NM; Gupta P; Ranjan A; Kim SH; Srivastava SK
Oncotarget; 2015 May; 6(13):11561-74. PubMed ID: 25869100
[TBL] [Abstract][Full Text] [Related]
66. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
[TBL] [Abstract][Full Text] [Related]
67. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Lu M; Fei Z; Zhang G
Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
[TBL] [Abstract][Full Text] [Related]
68. 6-C-(E-Phenylethenyl)Naringenin Attenuates the Stemness of Hepatocellular Carcinoma Cells by Suppressing Wnt/β-Catenin Signaling.
Kang Q; Gong J; Wang M; Wang Q; Chen F; Cheng KW
J Agric Food Chem; 2019 Dec; 67(50):13939-13947. PubMed ID: 31769973
[TBL] [Abstract][Full Text] [Related]
69. Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Kang D; Han Z; Oh GH; Joo Y; Choi HJ; Song JJ
Yonsei Med J; 2017 Sep; 58(5):899-909. PubMed ID: 28792132
[TBL] [Abstract][Full Text] [Related]
70. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
[TBL] [Abstract][Full Text] [Related]
71. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
72. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
73. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
74. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
[TBL] [Abstract][Full Text] [Related]
75. Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
Turcios L; Chacon E; Garcia C; Eman P; Cornea V; Jiang J; Spear B; Liu C; Watt DS; Marti F; Gedaly R
PLoS One; 2019; 14(2):e0212538. PubMed ID: 30794613
[TBL] [Abstract][Full Text] [Related]
76. Urolithin B suppresses tumor growth in hepatocellular carcinoma through inducing the inactivation of Wnt/β-catenin signaling.
Lv MY; Shi CJ; Pan FF; Shao J; Feng L; Chen G; Ou C; Zhang JF; Fu WM
J Cell Biochem; 2019 Oct; 120(10):17273-17282. PubMed ID: 31218741
[TBL] [Abstract][Full Text] [Related]
77. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
[TBL] [Abstract][Full Text] [Related]
78. Imperatorin induces Mcl-1 degradation to cooperatively trigger Bax translocation and Bak activation to suppress drug-resistant human hepatoma.
Li X; Zeng X; Sun J; Li H; Wu P; Fung KP; Liu F
Cancer Lett; 2014 Jun; 348(1-2):146-55. PubMed ID: 24680709
[TBL] [Abstract][Full Text] [Related]
79. Metallothionein 1H (MT1H) functions as a tumor suppressor in hepatocellular carcinoma through regulating Wnt/β-catenin signaling pathway.
Zheng Y; Jiang L; Hu Y; Xiao C; Xu N; Zhou J; Zhou X
BMC Cancer; 2017 Feb; 17(1):161. PubMed ID: 28241806
[TBL] [Abstract][Full Text] [Related]
80. Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the wnt signaling pathway.
Xu MX; Zhao L; Deng C; Yang L; Wang Y; Guo T; Li L; Lin J; Zhang L
Int J Oncol; 2013 Dec; 43(6):1951-9. PubMed ID: 24064724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]